硼替佐米治疗新诊断多发性骨髓瘤的临床观察  

Bortezomib plus chemotherapy for the treatment of newly diagnosed patients with multiple myeloma

作　　者：张纯[1] 陈智超[1] 刘芳[1] 刘新月[1] 刘凌波[1] 崔国惠[1] 邹萍[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院血液病研究所,湖北武汉430022

出　　处：《中国医院药学杂志》2009年第5期385-387,共3页Chinese Journal of Hospital Pharmacy

基　　金：国家自然科学基金资助项目(编号:30700882)

摘　　要：目的:观察硼替佐米联合化疗治疗新诊断多发性骨髓瘤(MM)患者的疗效和安全性。方法:11例新诊断MM患者分别采用单用硼替佐米、或联合地塞米松、或联合地塞米松+沙利度胺方案化疗,至少2～6个疗程。观察其疗效及不良反应。结果:中位随访8个月,11例患者中9例可评估,总有效率为88.8%,其中接近完全缓解4例(44.4%),部分缓解4例(44.4%),轻微缓解1例(11.2%)。最常见的不良反应为胃肠道症状、疲乏、血小板减少、周围神经病变以及感染等,通过对症治疗及调整剂量均可恢复。结论:硼替佐米对新诊断MM患者是一种疗效确切、可以耐受的治疗选择。OBJECTIVE To investigate the efficacy and toxicity of bortezomib plus chemotherapy for the treatment of newly diagnosed patients with multiple myeloma. METHODS 11 patients with newly diagnosed multiple myeloma were treated by bortezomib alone, or in combination with dexamethasone, or with dexamethasone and thalidomide. The patients had received two to six courses at least. Efficacy and ADR were observed. RESULTS The median follow-up duration from the beginning of bortezomib treatment was 8 months. Of 11 patients, 9 were eligible for the study. The overall response rate was 88. 8%, ineluding 4 almost response （44. 4%）, 4 partial response （44. 4%）, and i minimal response （11.2%）. The most common ADRs were gastrointestinal symptoms, fatigue, thrombocytopenia, peripheral neuropathy and infection. All the ADRs were manageable with symptomatic therapy or dose modification. CONCLUSION Bortezomib plus chemotherapy is an effective therapy with a high response rate and manageable toxicities for patients with newly diagnosed multiple myeloma.

关 键 词：多发性骨髓瘤 硼替佐米 地塞米松 沙利度胺 

分 类 号：R979.1[医药卫生—药品]